Sveriges Riksbank
| Bid procedure, 2021-01-29 | |
| Bonds | SWEDISH GOVERNMENT: 1053. SE0002829192. 2039-03-30 SWEDISH GOVERNMENT: 1056, SE0004517290, 2032-06-01 KINGDOM OF SWEDEN: 144A, XS2226974413, 2030-09-09 |
| Bid date | 2021-01-29 |
| Bid times | 09.00-10.00 (CET/CEST) on the Bid date |
| Requested volume (corresponding nominal amount) | 1053: 500 mln SEK +/-250 mln SEK 1056: 500 mln SEK +/-250 mln SEK 144A: 250 mln SEK +/-250 mln SEK |
| Highest permitted bid volume (corresponding nominal amount) | 1053: 500 mln SEK per bid 1056: 500 mln SEK per bid 144A: 250 mln SEK per bid |
| Lowest permitted bid volume (corresponding nominal amount) | SEK 50 million per bid |
| Expected allocation time | Not later than 10.15 (CET/CEST) on the Bid date |
| Delivery and payment date | 2021-02-02 |
| Delivery of bonds | To the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 |
Stockholm, 2021-01-22
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Teva Pharmaceutical Industries Ltd8.11.2025 00:00:00 CET | Press release
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
Columbus A/S7.11.2025 23:46:30 CET | Press release
Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them
Evaxion7.11.2025 23:10:00 CET | Press release
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
VALLOUREC7.11.2025 18:45:00 CET | Press release
VALLOUREC ANNOUNCES A TRANSITION IN ITS FINANCIAL MANAGEMENT
Trifork Group AG7.11.2025 18:29:08 CET | Press release
52/2025・Trifork Group: Reporting of transactions made by persons discharging managerial responsibilities
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
